An adult patient with pulmonary arterial hypertension, a NOTCH3 mutation, and leflunomide exposure

9 July 2024

Elizabeth G. FennerCatherine E. Simpson

https://doi.org/10.1002/pul2.12411

Abstract

Pulmonary arterial hypertension (PAH) is a poorly understood disease of the small pulmonary arteries. Pulmonary vascular remodeling and progressively rising pulmonary vascular resistance are hallmarks of the disease that ultimately result in right heart failure. Several genetic mutations, most notably in bone morphogenetic protein receptor type 2, have a causal association with heritable forms of PAH. Mutations in neurogenic locus notch homolog protein 3 (NOTCH3) have been reported in adults and children with PAH, but whether NOTCH3 is causally associated with PAH is debated. With this case report, we describe the clinical characteristics, comorbidities, and exposure history of an adult patient with PAH and multiple sclerosis who was found to have a NOTCH3 missense mutation and exposure to leflunomide.

Read the full case report

Share:
Additional comments are available to members. Login or register to become a member today